Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: snorkel who wrote (244)	1/26/1998 2:55:00 PM
From: David Rimer	Read Replies (1) \| Respond to of 1321

Genetronics Biomedical is a drug-delivery company on the Toronto Stock Exchange. The company has a drug-delivery system based on electroporation (using electric pulses to render cell walls porous). The company competes with Miravant and QLT as they are concentrating on oncology. Genetronics is targetting Head & Neck, Pancreas & Liver, Kaposi Sarcoma and other melanomas. They have a Phase II/III ongoing in the U.S. and Canada and are running trials (equivalent of Phase III)on all the above indications in France. The company has a market cap of US$40 million, has cash for 18 months and should be releasing results in the next 6 months. Compare and contrast with QLT or Miravant. Ciao David